A. Sanford

发表

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

A. Gajra, H. Ali, D. Spigel, 2018, Frontiers in Oncology.

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC

Edward S. Kim, C. Langer, J. Goldman, 2018, Front. Oncol..

Pleomorphic xanthoastrocytoma: favorable outcome after complete surgical resection.

T. Merchant, J. Langston, P. Burger, 2001, Neuro-oncology.

A phase I/II study of hyperfractionated radiotherapy in pediatric patients with brain stem gliomas

J. Krischer, P. Burger, C. Freeman, 1987 .

ABOUND.70+: Safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).

Edward S. Kim, C. Langer, J. Goldman, 2017 .

Safety and efficacy of nab-paclitaxel (nab-P)–based therapy in patients (pts) with non-small cell lung cancer (NSCLC) and performance status (PS) 2: Results from ABOUND.PS2.

A. Gajra, H. Ali, D. Spigel, 2017 .

Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) + carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2

M. Socinski, A. Gajra, H. Ali, 2016 .